George Kumar, Senior Director of Medical Diagnostics, Pan Tumor and GI Cancers at AstraZeneca, shared a post on LinkedIn:
“Breaking the “One Size Fits All” Barrier in Triple-Negative Breast Cancer (TNBC) Diagnostics
Predicting chemotherapy response in Triple-Negative Breast Cancer (TNBC) has long been a challenge due to the complex “crosstalk” between tumor cells and their microenvironment.
Today in Cell Reports Medicine, Dr. Wenyi Wang and the MD Anderson Cancer Center team introduced a new computational tool that uses a Tumor-specific total mRNA expression (TmS) biomarker. Unlike previous methods, this approach:
- Accounts for Aneuploidy: It factors in the abnormal chromosome numbers in cancer cells to get a true reading of mRNA activity.
- Decodes the Microenvironment: It separates tumor signals from surrounding non-tumor cells (deconvolution) to predict treatment response.
- Crosses Borders: Validated across a diverse cohort of 575 patients, proving its efficacy across Western and Asian ethnic groups.
This is a vital step toward making high-level bioinformatics accessible to the broader clinical community.”
Title: Tumor microenvironment transcriptional activity enables robust stratification of chemotherapy response in triple-negative breast cancer
Authors: Yaoyi Dai, Xiaoxi Pan, Shuai Guo, Shuangxi Ji, Shaolong Cao, Matthew D. Montierth, Yujie Jiang, Jeffrey T. Chang, Leming Shi, Shabnam Shalapour, Gloria V. Echeverria, Lucy Yates, Johan Staaf, Bora Lim, Yinyin Yuan, Wenyi Wang
Read the Full Article.
Other articles featuring George Kumar on OncoDaily.